Skip to main content

Table 1 HPV prevalence, fraction attributable to genotypes targeted by the 4-valent and nonavalent vaccines and potential absolute and relative benefit of the 9-valent vaccine compared to the 4-valent for each type of lesion

From: Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine

Lesion [sources] HPV prevalence HPV 6/11/16/18 attributable fraction among HPV+ cases HPV 6/11/16/18/31/33/45/52/58 attributable fraction among HPV+ cases HPV 31/33/45/52/58 absolute (relative) attributable fraction among HPV+ cases
Genital warts [2] 100% 90% 90% 0% (0%)
CIN 2/3 [2] 100% 45.5% 82.3% 36.8% (80.9%)
VIN2/3 [8] 86.9% 80.9% 93.9% 13.0% (16.1%)
VaIN 2/3 [9] 98.0% 65.7% 79.0% 13.3% (20.2%)
AIN 2/3 [22] 95.7% 80.5% 87.8% 7.3% (9.1%)
PIN 2/3 [10] 89.1% 81.0% 91.9% 10.9% (13.4%)
Cervical cancer [21] 100% 72.4%(a) 88.3%(a) 15.9% (21.9%)(a)
Vulvar cancer [8] 18.3% (b) 78.0% 91.6% 13.6% (17.4%)
Vaginal cancer [9] 71.0% 64.0%(a) 84.2%(a) 20.2% (31.6%)(a)
Anal cancer [22] 87.6% 84.3%(a) 92.3%(a) 8.0% (9.5%)(a)
Penile cancer [10] 32.2% 70.2%(a) 79.4%(a) 9.2% (13.1%)(a)
Oral cavity [23] 7.4% 72.0%(a) 80.6%(a) 8.6% (11.9%)(a)
Nasopharynx [23] 7,9% 75.0%(a) 87.5%(a) 12.5% (16.7%)(a)
Oropharynx cancer [23] 24.9% 85.2%(a) 89.7%(a) 4.5% (5.3%)(a)
Hypopharynx cancer [23] 3.9% 80.0%(a) 100%(a) 20.0% (25.0%)(a)
Pharynx cancer [23] 21.4% 66.7%(a) 66.7%(a) 0% (0%)(a)
Larynx cancer [23] 5.7% 57.6%(a) 74.6%(a) 17.0% (29.5%)(a)
  1. AIN: anal intraepithelial neoplasia; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; PIN: penile intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia
  2. (a) Genotypes 6 and 11 not included; (b) HPV attributable fraction estimated based on HPV DNA and p16 positivity